Learning, at least to me these issues are impossible to...

Learning, at least to me these issues are impossible to speculate, PBT2 or PBT434 or combination of them or an other molecule Prana has developed. IMO better to have PBT2 as an antibioticsynergistic molecule than 434 because it has been safe in humans by now.

Now if ever we have big problems for management to solve.
- agreement with universities discovered PBT2 to be antibioticsynergistic molecule
- new patent issue for this purpose 
- renegotiate with Sinclair group because of this new discovery
- possible new Big Pharma negotiations together with these universities, new interest is obvious because of new usage of PBT2
- planning new human studies with PBT2 in superinfections together with the universities

It is not a wonder that they do not tell us anything, these are very difficult issues. They have known the facts only 2 weeks and the Sinclair agreement has not approved by shareholders, yet.  Now it is time to get clever things done by the management.  We here on our sofa have not all the facts. 

But Learning, it may well be that Bohlmann et al have tested PBT434, who knows.